Immunome, Inc. IMNM
Set alert
At close · Oct 30
After hours · Oct 30, 6:47 PM ET
- YTD
- -15.22%
- 1 year
- +13.95%
- Open
- 18.25
- Prev close
- 18.29
- Mkt cap
- 2.15B
- Vol
- 1.27M
- Avg vol
- 1.28M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.82
- High
- 18.98
- Forward P/E
- -7.41
- Beta
- 2.56
- Short ratio
- 10.98
- Inst. own
- 102.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 22.64
- 200-d avg
- 22.51
- 1y target
- 35.33
5D chart
Events in this range
- Oct 27, 2026Rating: Wedbush · Outperform → Outperform
Signals (126)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:50 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
News
-
2 days ago benzinga.com
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary…
2 days ago businesswire.com
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…
-
5 days ago benzinga.com
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.
-
6 days ago benzinga.com
Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE…
6 days ago businesswire.com
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…
3 weeks ago businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer…
-
1 month ago benzinga.com
Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24
Stifel analyst Dara Azar initiates coverage on Immunome (NASDAQ:IMNM) with a Hold rating and announces Price Target of $24.
-
1 month ago benzinga.com
Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and…
1 month ago businesswire.com
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…
-
1 month ago benzinga.com
Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32
Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
1 month ago benzinga.com
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
1 month ago businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer…
2 months ago businesswire.com
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today…
2 months ago marketbeat.com
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients…
2 months ago globenewswire.com
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained…
2 months ago seekingalpha.com
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat's NDA and a PDUFA date set for April 2027. The company's pipeline is diversified,…
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.
-
2 months ago benzinga.com
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per…
2 months ago businesswire.com
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial…
2 months ago businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced…
2 months ago benzinga.com
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.
3 months ago defenseworld.net
Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM
Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and…
-
3 months ago benzinga.com
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
3 months ago businesswire.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the…
3 months ago fool.com
What This Immunome Sale Means a Day Before a Big FDA Milestone
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in…
3 months ago zacks.com
Immunome Stock Up 32% in a Month: Here's What You Should Know
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
3 months ago benzinga.com
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review
FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.
-
3 months ago benzinga.com
Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action Date
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or…
3 months ago businesswire.com
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S.…
3 months ago businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced…
-
4 months ago benzinga.com
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
4 months ago gurufocus.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
-
4 months ago benzinga.com
Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid Tumors
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the…
4 months ago businesswire.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the…
4 months ago seekingalpha.com
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
-
5 months ago benzinga.com
Truist Securities Maintains Buy on Immunome, Raises Price Target to $37
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $36 to $37.
-
5 months ago benzinga.com
Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36
Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $36.
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
-
5 months ago benzinga.com
Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.57) by 15.79 percent. This is a 7.69 percent increase over losses of $(0.52) per…
-
6 months ago benzinga.com
Immunome Reveals Oral Presentation Of Phase 3 RINGSIDE Data At 2026 ASCO Annual Meeting
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its…
8 months ago benzinga.com
This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
9 months ago benzinga.com
The Insider Report: Batten Down the Hatches
The Insider Report: Batten Down the Hatches
10 months ago benzinga.com
Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday
Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
1 year ago benzinga.com
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined…